Exicure, Inc. (NASDAQ:XCUR) Sees Significant Decrease in Short Interest

Exicure, Inc. (NASDAQ:XCUR) saw a significant decline in short interest during the month of August. As of August 14th, there was short interest totaling 60,402 shares, a decline of 43.8% from the July 30th total of 107,470 shares. Based on an average trading volume of 43,727 shares, the days-to-cover ratio is currently 1.4 days. Approximately 2.0% of the company’s stock are sold short.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings downgraded shares of Exicure from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, June 11th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company currently has an average rating of “Sell”.

Exicure Trading Down 8.5%

Shares of NASDAQ:XCUR opened at $1.29 on Friday. The firm has a 50 day simple moving average of $1.70 and a 200-day simple moving average of $2.94. Exicure has a twelve month low of $1.05 and a twelve month high of $9.48. The company has a market capitalization of $8.45 million, a PE ratio of -0.98 and a beta of 3.65.

Exicure (NASDAQ:XCUR) last announced its quarterly earnings results on Friday, August 14th. The company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($18.60) by $18.42.

Exicure Company Profile

Exicure is a clinical‐stage biotechnology company pioneering the development of next‐generation genetic medicines through its proprietary spherical nucleic acid (SNA) delivery platform. This nanotechnology‐based approach is designed to facilitate the intracellular delivery of oligonucleotide therapeutics, addressing longstanding challenges in targeting hard‐to‐reach tissues such as the central nervous system.

The company’s pipeline encompasses programs for neurological disorders—including Huntington’s disease, Parkinson’s disease and Alzheimer’s disease—as well as exploratory efforts in dermatological indications and oncology.